IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (1729)	12/18/2000 3:51:26 PM
From: Maurice Winn	1 Recommendation of 1762

<Epratuzumab binds to a different cell surface protein (CD22) than Rituxan (CD20).> Sounds good. Inject [or infuse] something which binds to everything unique which cancer cells exhibit, from CD1 to CD1000, telomerase production, size, shape or whatever, either simultaneously or sequentially. I suppose simultaneously would be better - if the person didn't look like a balloon after being filled with 1000 different antigen markers. Mqurice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next